Sara Hurvitz, MD

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

Sara A. Hurvitz, MD, discusses the evolution of targeted therapies in HER2-positive breast cancer.

Highlights from the OlympiA trial, which evaluated the use of olaparib in the adjuvant setting in patients with high-risk BRCA-mutated breast cancer.

Joyce O'Shaughnessy, MD, provides a brief overview of novel neoadjuvant and adjuvant treatment approaches being investigated in the setting of breast cancer.

Sara A. Hurvitz, MD, discusses the benefit of trastuzumab deruxtecan in a subset of patients with HER2-positive breast cancer and active brain metastases in the phase 3 DESTINY-Breast03 trial.

Sara A. Hurvitz, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Sara A. Hurvitz, MD, discusses the incidence of male breast cancer in the United States.

Sara A. Hurvitz, MD, discusses the expanding HER2-positive metastatic breast cancer treatment arsenal.

Sara Hurvitz, MD, associate professor, David Geffen School of Medicine, UCLA; medical director, Jonsson Comprehensive Cancer Center Clinical Research Unit; co-director, Santa Monica-UCLA Outpatient Oncology Practices; and director, Breast Cancer Clinical Trials Program, UCLA, discusses the potential global impact of biosimilars in breast cancer.

Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses when to use a biosimilar over the originator drug.

Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses biosimilars in breast cancer.

Sara Hurvitz, MD, Associate Professor of Medicine at UCLA, discusses treatment options for patients with HER2-positive breast cancer.

Sara Hurvitz, MD, Associate Professor of Medicine at UCLA, discusses data supporting the elimination of anthracyclines in HER2-positive breast cancer treatment.

Sara Hurvitz, MD, medical oncologist, General Internal Medicine, Hematology and Oncology at UCLA, discusses steps needed to take in the field of HER2-positive breast cancer from a research perspective.

Sara Hurvitz, MD, medical oncologist, General Internal Medicine, Hematology and Oncology at UCLA, discusses neoadjuvant treatment options for patients with HER2-positive breast cancer.

Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, gives an overview of treatment hypotheses for triple-negative breast cancer (TNBC).

Through a variety of research roles, Sara Hurvitz, MD, is exploring novel targeted therapies for the treatment of breast cancer, including developing and implementing clinical trials. Her interests include the phosphatidylinositol 3-kinase (PI3K) signaling pathway.